All About Chemistry... 2011 and beyond

Related Stories

YEDA R&D and XL-Protein Sign Agreement to Bring Interferon Superagonist to Market

Released: 22-Oct-2014 11:00 AM EDT
Source Newsroom: Weizmann Institute of Science
Contact Information

Available for logged-in reporters only

Citations Journal of Biological Chemistry, 2014 289: 29014-29029

Oct. 23, 2014 - YEDA Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist – PAS-YNSα8 – which has been jointly developed by scientists at the Weizmann Institute and at XL-protein. Under this agreement, YEDA acquires the worldwide exclusive rights for marketing and out-licensing of this compound.

One of the potential uses of PAS-YNSα8 is for treatment of inflammatory diseases; in particular, those of the central nervous system. An example is multiple sclerosis (MS), a devastating, chronic, and progressive immune disease that can eventually lead to paralysis. Among the drugs today used to treat MS are those based on interferon-beta (IFN-beta).

Weizmann Institute scientists developed a novel, highly active interferon variant, YNSα8. This modified IFN was engineered to bind much more tightly to the interferon receptors. The result is a very potent molecule, which shows a gene activation profile and biological activities that surpass any naturally existing interferon.

Working with scientists at XL-protein, the activity of PAS-YNSα8 was boosted by extending its half-life in the body using PASylation® technology. PASylation involves the genetic fusion of the therapeutic protein or peptide with a non-structured, expanded polypeptide made of the small amino acids Pro, Ala, and Ser (PAS).

In a study that appeared in the Journal of Biological Chemistry and was led by Weizmann’s Dr. Daniel Harari and Prof. Gideon Schreiber, it was found that the in vivo half-life of PAS-YNSα8 was increased tenfold over standard interferon. Most importantly, the PASylation did not interfere with the biological activity of this potent IFN; this has been a common technical problem for other methods of extending drug circulation. In a head-to-head comparison with conventional IFN-beta, this long-living superagonist conferred highly improved protection from disease progression in a mouse model of human MS, despite being injected four times less often than IFN-beta and at one-sixteenth of the dosage.

“We are excited by the pronounced therapeutic effect of our PASylated IFN superagonist, which was not accompanied by any observable immunogenic side effects in mice,” said Prof. Schreiber. “Our studies suggest that this potential drug could be safe and might provide clinical benefit surpassing that of IFN-beta, all this with a significantly reduced number of injections and lower dosage. We hope it will soon be possible to check the effectiveness of our molecule in clinical trials in humans.”

Prof. Arne Skerra, CSO of XL-protein and co-author of the study, stated: “The biological potency and bioavailability of this novel IFN-based molecule is remarkable. Improved receptor binding, achieved by advanced protein engineering, in synergy with the half-life extension provided by our PASylation technology, will result in more effective and less frequent dosing for the benefit of patients.”

“We are pleased to forge this business alliance with a renowned partner such as YEDA to commercialize this potent biological drug candidate,” added Claus Schalper, CEO of XL-protein.

Prof. Gideon Schreiber and Dr. Daniel Harari acknowledge the generous financial support of Merck Serono for the study in mice with EAE.

Prof. Gideon Schreiber’s research is supported by the Dana and Yossie Hollander Center for Structural Proteomics, which he heads, and the R Baby Foundation.

About YEDA
YEDA Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. YEDA initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by Weizmann Institute of Science researchers. YEDA holds an exclusive agreement with the Weizmann Institute of Science to market and commercialize its intellectual property and generate income to support further research and education.

For more information, please visit:

About XL-protein GmbH
XL-protein GmbH is a privately owned biopharmaceutical company based in Freising, Germany, which exploits its proprietary PASylation® technology to develop second-generation biopharmaceuticals with extended half-life and superior in vivo activity. PASylation® is a fully biological technology that can be applied both to approved biologics to yield follow-on drug products (“biobetters”) or to innovative therapeutic proteins or peptides, allowing less frequent and more effective dosing combined with better patient tolerability.

For more information, please visit:


Share this story with your friends!

Social Networking

Please recommend us on Facebook, Twitter and more:

Other social media tools

Global Partners

Tell us what you think of Chemistry 2011 -- we welcome both positive and negative comments. Have any problems using the site? Questions?

About us

Chemistry2011 is an informational resource for students, educators and the self-taught in the field of chemistry. We offer resources such as course materials, chemistry department listings, activities, events, projects and more along with current news releases.

Events & Activities

Are you interested in listing an event or sharing an activity or idea? Perhaps you are coordinating an event and are in need of additional resources? Within our site you will find a variety of activities and projects your peers have previously submitted or which have been freely shared through creative commons licenses. Here are some highlights: Featured Idea 1, Featured Idea 2.

About you

Ready to get involved? The first step is to sign up by following the link: Join Here. Also don’t forget to fill out your profile including any professional designations.

Global Partners